Nevada Fake Moon Bay Wall is Seen in The Background.
Music- Symphony No.94, In G Major, 'The Surprise': Adagio Cantabile
This video as you hear & see it, is located for download at NASA site:
http://history.nasa.gov/alsj/a15/video15.html
Apollo 15 Video Library
Deploying the Lunar Roving Vehicle
Journal Text: 119:58:00
ALL NASA FOOTAGE USED IN THIS VIDEO IS PUBLIC DOMAIN. THE USE OF ANY COPYRIGHTED MATERIAL IS USED UNDER THE GUIDELINES OF "FAIR USE" IN TITLE 17 § 107 OF THE UNITED STATES CODE. SUCH MATERIAL REMAINS THE COPYRIGHT OF THE ORIGINAL HOLDER AND IS USED HERE FOR THE PURPOSES OF EDUCATION, COMPARISON, AND CRITICISM ONLY. NO INFRINGEMENT OF COPYRIGHT IS INTENDED.
When her father is killed by the notorious Rose Riders for a mysterious journal that reveals the secret location of a gold mine, eighteen year-old Kate Thompson disguises herself as a boy and takes to the gritty plains looking for answers—and justice. In the spirit of True Grit, acclaimed young adult novelist Erin Bowman brings to life the unpredictable and cutthroat days of the Wild West. Find out more at http://www.embowman.com/ and http://www.hmhco.com/ #VengeanceRoad historical romance/YA
After only 16 weeks of existence, foetuses hear and respond to music as long as it is emitted from their mother’s vagina. Foetuses respond to this stimulus by opening their mouths and pulling their tongues out as far as possible, making vocalisation movements – prior to the acquisition of language.
This is the main conclusion of the study conducted by the team of Institut Marquès, which boasts the collaboration of Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona.
The study, entitled “Foetal facial expression in response to intravaginal music emission”, is published this week in the journal Ultrasound of the British Medical Ultrasound Society (BMUS).
According to Dr. Marisa López-Teijón, the Head of Assisted Reproduction at Institut Marquès and the principal researcher and author of the clinical study: “We have discovered that the formula for foetuses to hear like us is to emit music from the mother’s vagina. They barely hear the sound that reaches them through their mother’s abdomen: the soft tissues of the abdomen and the inside of the mother’s body absorb the soundwaves”.
To view the multimedia release go to:
http://www.multivu.com/players/English/7647351-how-foetuses-hear-musical-stimuli/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer. The study from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project appears in the November 19 edition of the New England Journal of Medicine.
Ultimately, researchers anticipate that systematic monitoring of patients and family members who have germline mutations in cancer predisposition genes will allow the detection of cancers at their earliest and most curable stage, thereby improving the outcomes for these children and family members.
To view the multimedia release go to:
http://www.multivu.com/players/English/7692851-st-jude-hospital-genome-project/
PDI, a leader in infection prevention products and solutions, announced the launch of its new EASY SCREEN™ CLEANING WIPE. This new product addresses the increasing use of touchscreen equipment in healthcare and the need for compatible cleaning products.
According to the Epocrates 2014 Mobile Trends Report, the presence of “digital omnivores,” a clinician regularly using digital devices including tablets, smartphones and computers, was 41 percent in 2014 and was predicted to increase to 74 percent in 2015. One of the biggest surges was expected to come from tablet usage, going from 45 percent in 2014 to 80 percent in 2015. Withstanding the apparent increase in touchscreen device usage in healthcare, a June 2015 study in the American Journal of Infection Control stated that proper protocols are lacking to address sensitive surfaces like touchscreen devices.
“Healthcare facilities are advancing everyday and it’s vital that we, as infection prevention leaders, are aware of the changes that are happening and able to adapt quickly. We created the EASY SCREEN™ CLEANING WIPE in response to the increasing usage of touchscreens and the need for a compatible product that wouldn’t damage the technology,” said PDI Senior Product Manager, Melanie Waddell.
To view the multimedia release go to:
http://www.multivu.com/players/English/7782451-pdi-easy-screen-cleaning-wipe/
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
